Literature DB >> 30354205

Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants.

Annakaisa Tirronen1, Taina Vuorio1, Sanna Kettunen1, Krista Hokkanen1, Bastian Ramms2,3, Henri Niskanen1, Hanne Laakso1, Minna U Kaikkonen1, Matti Jauhiainen4, Philip L S M Gordts2,5, Seppo Ylä-Herttuala1,6.   

Abstract

Objective- Dyslipidemia is one of the key factors behind coronary heart disease. Blood and lymphatic vessels play pivotal roles in both lipoprotein metabolism and development of atherosclerotic plaques. Recent studies have linked members of VEGF (vascular endothelial growth factor) family to lipid metabolism, but the function of VEGF-D has remained unexplored. Here, we investigated how the deletion of VEGF-D affects lipid and lipoprotein metabolism in atherogenic LDLR-/- ApoB100/100 mice. Approach and Results- Deletion of VEGF-D (VEGF-D-/-LDLR-/-ApoB100/100) led to markedly elevated plasma cholesterol and triglyceride levels without an increase in atherogenesis. Size distribution and hepatic lipid uptake studies confirmed a delayed clearance of large chylomicron remnant particles that cannot easily penetrate through the vascular endothelium. Mechanistically, the inhibition of VEGF-D signaling significantly decreased the hepatic expression of SDC1 (syndecan 1), which is one of the main receptors for chylomicron remnant uptake when LDLR is absent. Immunohistochemical staining confirmed reduced expression of SDC1 in the sinusoidal surface of hepatocytes in VEGF-D deficient mice. Furthermore, hepatic RNA-sequencing revealed that VEGF-D is also an important regulator of genes related to lipid metabolism and inflammation. The lack of VEGF-D signaling via VEGFR3 (VEGF receptor 3) led to lowered expression of genes regulating triglyceride and cholesterol production, as well as downregulation of peroxisomal β-oxidation pathway. Conclusions- These results demonstrate that VEGF-D, a powerful lymphangiogenic and angiogenic growth factor, is also a major regulator of chylomicron metabolism in mice.

Entities:  

Keywords:  cholesterol; chylomicron remnants; hyperlipidemia; triglyceride; vascular endothelial growth factor D

Mesh:

Substances:

Year:  2018        PMID: 30354205     DOI: 10.1161/ATVBAHA.118.311549

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  10 in total

1.  Vascular Endothelial Growth Factor-D (VEGF-D) Overexpression and Lymphatic Expansion in Murine Adipose Tissue Improves Metabolism in Obesity.

Authors:  Adri Chakraborty; Sheridan Barajas; Gabriela M Lammoglia; Andrea J Reyna; Thomas S Morley; Joshua A Johnson; Philipp E Scherer; Joseph M Rutkowski
Journal:  Am J Pathol       Date:  2019-03-13       Impact factor: 4.307

Review 2.  Annual Report on Sex in Preclinical Studies: Arteriosclerosis, Thrombosis, and Vascular Biology Publications in 2018.

Authors:  Hong S Lu; Ann Marie Schmidt; Robert A Hegele; Nigel Mackman; Daniel J Rader; Christian Weber; Alan Daugherty
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-12-23       Impact factor: 8.311

Review 3.  Arterial Lymphatics in Atherosclerosis: Old Questions, New Insights, and Remaining Challenges.

Authors:  Gábor Csányi; Bhupesh Singla
Journal:  J Clin Med       Date:  2019-04-11       Impact factor: 4.241

Review 4.  The Intestinal Lymphatic System: Functions and Metabolic Implications.

Authors:  Vincenza Cifarelli; Anne Eichmann
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-12-14

Review 5.  The Role of Lymphatic Vascular Function in Metabolic Disorders.

Authors:  Pieter R Norden; Tsutomu Kume
Journal:  Front Physiol       Date:  2020-05-05       Impact factor: 4.566

6.  Distinct Characteristics of VEGF-D and VEGF-C to Predict Mortality in Patients With Suspected or Known Coronary Artery Disease.

Authors:  Hiromichi Wada; Masahiro Suzuki; Morihiro Matsuda; Yoichi Ajiro; Tsuyoshi Shinozaki; Satoru Sakagami; Kazuya Yonezawa; Masatoshi Shimizu; Junichi Funada; Takashi Takenaka; Yukiko Morita; Toshihiro Nakamura; Kazuteru Fujimoto; Hiromi Matsubara; Toru Kato; Takashi Unoki; Daisuke Takagi; Kyohma Wada; Miyaka Wada; Moritake Iguchi; Nobutoyo Masunaga; Mitsuru Ishii; Hajime Yamakage; Toru Kusakabe; Akihiro Yasoda; Akira Shimatsu; Kazuhiko Kotani; Noriko Satoh-Asahara; Mitsuru Abe; Masaharu Akao; Koji Hasegawa
Journal:  J Am Heart Assoc       Date:  2020-04-22       Impact factor: 5.501

7.  Levels of pretreatment blood lipids are prognostic factors in advanced NSCLC patients treated with anlotinib.

Authors:  Mengqiu Tang; Chao Song; Yaowen Zhang; Xiaoyu Xu; Chen Wang; Zhanchun Zhang; Tian Chen
Journal:  Lipids Health Dis       Date:  2021-11-20       Impact factor: 3.876

8.  Dysregulated Serum Lipid Metabolism Promotes the Occurrence and Development of Diabetic Retinopathy Associated With Upregulated Circulating Levels of VEGF-A, VEGF-D, and PlGF.

Authors:  Xinyuan Zhang; Bingjie Qiu; Qiyun Wang; Sobha Sivaprasad; Yanhong Wang; Lin Zhao; Rui Xie; Lei Li; Wenting Kang
Journal:  Front Med (Lausanne)       Date:  2021-11-22

Review 9.  Hypercholesterolemia and Lymphatic Defects: The Chicken or the Egg?

Authors:  Takuro Miyazaki; Akira Miyazaki
Journal:  Front Cardiovasc Med       Date:  2021-06-23

Review 10.  The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets.

Authors:  Siarhei A Dabravolski; Victoria A Khotina; Andrey V Omelchenko; Vladislav A Kalmykov; Alexander N Orekhov
Journal:  Int J Mol Sci       Date:  2022-01-15       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.